Company: INCR
Filing Date: 2025-05-01
Form Type: 20-F
Source: 0001641172-25-007971
Chunk: 99

Company: Intercure Ltd.
Filing Date: 2025-05-01
Form: 20-F
Item: Item 5
Chunk 99
---
 of cannabis strains. In addition, we have invested in a production system that adheres to the strictest regulatory and quality standards. In doing so, we achieve the highest standard of product quality for our patients and for commercial research collaborations. We believe this will enable us to enter into future target markets and strategic partnerships, expanding our leadership globally.
 
Nasdaq Listing
 
Our ordinary shares are traded on both the Nasdaq and TASE under the ticker symbol “INCR”.
 

72
--
Full Year 2024 Key Financial & Operating Highlights
 
For InterCure (on a consolidated basis): 
 

●                                         Our consolidated net loss for the year ended December 31, 2024 was NIS                                     
    73 million, compared to a consolidated net loss of NIS 64 million for the year ended December 31, 2023. The net loss of includes non-cash amounts
         such as impairments of goodwill and credit risk. The net loss includes non-cash amounts such as impairments of goodwill and credit risk.    
-----------------------------------------------------------------------------------------------------------------------------------------------------
●   Fiscal year 2024 revenue and Adjusted EBITDA of NIS 239 million and NIS 18 million, respectively.                                                
●   Negative                                                                                                                                         
    cash from operations of NIS 67 million for the year ended December 31, 2024 compared to negative cash from operations of NIS 54                  
    million for the year ended December 31, 2023.                                                                                                    
●   According                                                                                                                                        
    to Israeli Law, due to the location of the Company’s Southern Facility, the Company is entitled to receive from Israeli authorities              
    full compensation for all the direct and indirect damages caused to the Southern Facility by the terrorist attack and the war in Gaza.           
    InterCure’s management and its advisers are working diligently with the Israeli authorities to obtain this full compensation. To                 
    date, the Company has already received NIS 82 million as advance payments from the Israeli authorities in relation to                            
    such compensation.                                                                                                                               
●   Cash                                                                                                                                             
    and cash equivalents and restricted cash of NIS 80 million on December 31, 2024 compared to NIS 111 million on December 31, 2023.                

73
--
Results of Operations
 
For a discussion of our results of operations for the year ended December 31, 2022, including a year-to-year comparison between 2023 and 2022, and a discussion of our liquidity and capital resources for the year ended December